Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1).’ The study aims to evaluate the effectiveness and safety of Orforglipron, an oral medication, in adults with obesity or overweight conditions accompanied by related health issues.
The intervention being tested is Orforglipron, a drug administered orally, designed to treat obesity and overweight conditions. The study includes three experimental groups receiving different doses of Orforglipron and a placebo group for comparison.
This interventional study is randomized with a parallel assignment model and double masking, meaning both participants and investigators are unaware of which treatment participants receive. The primary purpose is to assess treatment efficacy.
The study began on June 5, 2023, with the primary completion and estimated study completion dates yet to be announced. The last update was submitted on August 11, 2025, indicating ongoing progress.
The outcome of this study could significantly influence Eli Lilly’s market position, potentially boosting investor confidence and impacting stock performance positively. As obesity treatments are a competitive field, successful results could position Eli Lilly favorably against competitors.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.